Cargando…

Cabergoline, Dopamine D2 Receptor Agonist, Prevents Neuronal Cell Death under Oxidative Stress via Reducing Excitotoxicity

Several lines of evidence demonstrate that oxidative stress is involved in the pathogenesis of neurodegenerative diseases, including Parkinson's disease. Potent antioxidants may therefore be effective in the treatment of such diseases. Cabergoline, a dopamine D2 receptor agonist and antiparkins...

Descripción completa

Detalles Bibliográficos
Autores principales:	Odaka, Haruki, Numakawa, Tadahiro, Adachi, Naoki, Ooshima, Yoshiko, Nakajima, Shingo, Katanuma, Yusuke, Inoue, Takafumi, Kunugi, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051758/ https://www.ncbi.nlm.nih.gov/pubmed/24914776 http://dx.doi.org/10.1371/journal.pone.0099271

Ejemplares similares

Glucocorticoid affects dendritic transport of BDNF-containing vesicles
por: Adachi, Naoki, et al.
Publicado: (2015)

The Role of Brain-Derived Neurotrophic Factor in Comorbid Depression: Possible Linkage with Steroid Hormones, Cytokines, and Nutrition
por: Numakawa, Tadahiro, et al.
Publicado: (2014)

Actions of Brain-Derived Neurotrophic Factor and Glucocorticoid Stress in Neurogenesis
por: Numakawa, Tadahiro, et al.
Publicado: (2017)

Actions of Brain-Derived Neurotrophin Factor in the Neurogenesis and Neuronal Function, and Its Involvement in the Pathophysiology of Brain Diseases
por: Numakawa, Tadahiro, et al.
Publicado: (2018)

Impact of glucocorticoid on neurogenesis
por: Odaka, Haruki, et al.
Publicado: (2017)

The Sox2 promoter-driven CD63-GFP transgenic rat model allows tracking of neural stem cell-derived extracellular vesicles
por: Yoshimura, Aya, et al.
Publicado: (2018)

Brain-Derived Neurotrophic Factor Signaling in the Pathophysiology of Alzheimer’s Disease: Beneficial Effects of Flavonoids for Neuroprotection
por: Numakawa, Tadahiro, et al.
Publicado: (2021)

The Role of Neurotrophin Signaling in Age-Related Cognitive Decline and Cognitive Diseases
por: Numakawa, Tadahiro, et al.
Publicado: (2022)

Small noncoding vault RNA modulates synapse formation by amplifying MAPK signaling
por: Wakatsuki, Shuji, et al.
Publicado: (2021)

Outcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndrome
por: Movahedi, Shohreh, et al.
Publicado: (2016)

Conscious perception and the modulatory role of dopamine: no effect of the dopamine D2 agonist cabergoline on visual masking, the attentional blink, and probabilistic discrimination
por: Boonstra, E.A, et al.
Publicado: (2020)

Protective Action of Neurotrophic Factors and Estrogen against Oxidative Stress-Mediated Neurodegeneration
por: Numakawa, Tadahiro, et al.
Publicado: (2011)

Generation of a novel transgenic rat model for tracing extracellular vesicles in body fluids
por: Yoshimura, Aya, et al.
Publicado: (2016)

Dopamine protects neurons against glutamate-induced excitotoxicity
por: Vaarmann, A, et al.
Publicado: (2013)

A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How?
por: Costello, Leslie C., et al.
Publicado: (2019)

An in vitro reproduction of stress-induced memory defects: Effects of corticoids on dendritic spine dynamics
por: Saito, Shinichi, et al.
Publicado: (2016)

SAT063 Dopaminergic Agonist Cabergoline Inhibits Autophagic Flux In Beta Pancreatic Cells
por: Francisco Mendez, Luis, et al.
Publicado: (2023)

Novel Drug Candidates Improve Ganglioside Accumulation and Neural Dysfunction in GM1 Gangliosidosis Models with Autophagy Activation
por: Kajihara, Ryutaro, et al.
Publicado: (2020)

The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
por: Hori, Hiroaki, et al.
Publicado: (2012)

Possible protective action of neurotrophic factors and natural compounds against common neurodegenerative diseases
por: Numakawa, Tadahiro
Publicado: (2014)

FRI294 The Dopamine Agonist Cabergoline Targets Multiple Pathways To Inhibit PRL Secretion And Increases Stromal Fibrosis Via The Serotonin Receptor 5HTR1F
por: Zhang, Dongyun, et al.
Publicado: (2023)

Peripartum Cardiomyopathy with the Cardiac Function Restored by Cabergoline
por: Shibuya, Yuki, et al.
Publicado: (2022)

Remission in Cushing disease with cabergoline
por: Gopal, Raju, et al.
Publicado: (2008)

Suppression of mTOR pathway and induction of autophagy-dependent cell death by cabergoline
por: Lin, Shao Jian, et al.
Publicado: (2015)

Neurotrophins and Other Growth Factors in the Pathogenesis of Alzheimer’s Disease
por: Numakawa, Tadahiro, et al.
Publicado: (2023)

Involvement of brain-derived neurotrophic factor signaling in the pathogenesis of stress-related brain diseases
por: Numakawa, Tadahiro, et al.
Publicado: (2023)

Editorial: Excitotoxicity Turns 50. The Death That Never Dies
por: Granzotto, Alberto, et al.
Publicado: (2022)

GABA Receptor Agonists Protect From Excitotoxic Damage Induced by AMPA in Oligodendrocytes
por: Bayón-Cordero, Laura, et al.
Publicado: (2022)

Cabergoline Treatment in Invasive Giant Prolactinoma
por: Alsubaie, Sadeem, et al.
Publicado: (2014)

SAT-270 Priapism Secondary to Cabergoline
por: Amir, Maryam, et al.
Publicado: (2020)

The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas
por: Liu, Xiaoshuang, et al.
Publicado: (2019)

Effects of Pituitary Surgery and High-Dose Cabergoline Therapy on Metabolic Profile in Patients With Prolactinoma Resistant to Conventional Cabergoline Treatment
por: Pirchio, Rosa, et al.
Publicado: (2021)

DRD2 Agonist Cabergoline Abolished the Escape Mechanism Induced by mTOR Inhibitor Everolimus in Tumoral Pituitary Cells
por: Mangili, Federica, et al.
Publicado: (2022)

Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to excitotoxic death
por: Carlson, Noel G, et al.
Publicado: (2010)

HIP/PAP prevents excitotoxic neuronal death and promotes plasticity
por: Haldipur, Parthiv, et al.
Publicado: (2014)

The Effectiveness of Cabergoline for the Prevention of Ovarian Hyperstimulation Syndrome
por: Hosseini, Marzieh Agha, et al.
Publicado: (2011)

Remission with Cabergoline in Adolescent Boys with Cushing’s Disease
por: Güven, Ayla, et al.
Publicado: (2013)

Spontaneous reduction of prolactinoma post cabergoline withdrawal
por: Venkatesh, Sampath Kumar, et al.
Publicado: (2012)

Pituitary Apoplexy during Treatment of Prolactinoma with Cabergoline
por: Ghadirian, Hesam, et al.
Publicado: (2018)

A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells
por: Di Muro, Genesio, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k2vbe7f4icpk0u5ev1doq5jcf2